Morgan Stanley raised the firm’s price target on Novo Nordisk to DKK 700 from DKK 685 and keeps an Overweight rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVO:
- Novo Nordisk, Valo collaborate to develop treatments using human data, AI
- Weight-loss drugs are bad news for medtech makers, Barron’s says
- BCBSM modifying weight loss drug coverage to require ‘lifestyle modifications’
- Goldman says BCBSM modifications to GLP-1 coverage positive for WW
- Notable open interest changes for September 21st